The 6 most recent market catalysts affecting $STVN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 4, 2026
Corporate Catalyst
Bearish
Impact 75
William Blair Downgrades Stevanato Group to Market Perform
William Blair downgraded Stevanato Group (STVN) from Outperform to Market Perform, mirroring a recent UBS price target reduction. This action stems directly from Stevanato's Q3 202…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Stevanato Group, Lowers Price Target to $23
UBS analyst Dan Leonard has lowered the price target for Stevanato Group (STVN) from $28 to $23, while maintaining a 'Neutral' rating. This action suggests that UBS sees less upsid…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Stevanato Group Lowers FY2026 GAAP EPS Guidance from $0.64-$0.69 to $0.62-$0.64; Lowers FY2026 Sales Guidance from $1.467B-$1.500B to $1.465B-$1.488B
Stevanato Group (STVN) has lowered its FY2026 GAAP EPS guidance from $0.64-$0.69 to $0.62-$0.64 and its sales outlook from $1.467 billion-$1.500 billion to $1.465 billion-$1.488 bi…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Stevanato Group Narrows FY2026 Adj EPS Guidance from $0.69-$0.73 to $0.70-$0.72 vs $0.68 Est; Lowers FY2026 Sales Guidance from $1.467B-$1.500B to $1.465B-$1.488B vs $1.500B Est
Stevanato Group (STVN) has updated its FY2026 guidance, which is a significant event for investors. While the adjusted EPS guidance was narrowed and the lower end slightly raised, …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Stevanato Gr Q2 Adj. EPS $0.16 Beats $0.14 Estimate, Sales $351.091M Miss $351.370M Estimate
Stevanato Group's Q2 earnings report shows a mixed but generally positive picture. The significant beat on adjusted EPS, coupled with a healthy year-over-year increase, suggests st…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In Europe
Stevanato Group announced that its Alina pen injector platform, used in liraglutide-based combination products for diabetes and weight management, has received marketing authorizat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.